1. Ries LAG, Eisner MP, Kosary CL, et al (Eds). SEER Cancer Statistics Review, 1975–2002, Bethesda, National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission. Accessed June 1, 2006.
2. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer;Yang;N Engl J Med,2003
3. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2006
4. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC);Escudier;Eur J Cancer,2005
5. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC;Gallou;Hum Mutat,1999